Neurofibromatosis Clinical Trials Consortium
The Neurofibromatosis Clinical Trials Consortium (NFCTC, http://www.uab.edu/nfconsortium) was established by the Department of Defense Neurofibromatosis Research Program (NFRP) to develop and perform clinical trials for the treatment of neurofibromatosis (NF) complications in children and adults. The Consortium is composed of thirteen clinical sites, six collaborating sites, and an Operations Center at the University of Alabama at Birmingham under the direction of Dr. Bruce Korf. The purpose of the Operations Center is to provide administrative, data management, and statistical support to the NFCTC. Each of the clinical and collaborating sites has expertise in the treatment and management of NF and an established patient population available for clinical trials.
Management and Oversight to the NFCTC is provided by three independent committees:
The Consortium Steering Committee (CSC) membership is constituted by the Consortium Operations Center Principal Investigator (PI) and the PI of each clinical trial site. The CSC is responsible for proposing and conducting phase I and II clinical evaluations of promising therapeutic agents for the management or treatment of NF and for determining which trial sites will participate in each study.
The External Review Committee (ERC) consists of eight scientists and clinicians who have significant expertise in clinical trials. The ERC is responsible for advising the Operations Center PI and CSC by conducting peer review of new protocols for the clinical trials.
The External Advisory Board (EAB) is comprised of selected members of the NFRP Integration Panel and additional ad hoc representatives. The EAB is responsible for providing independent expertise and advice to the NFRP regarding Consortium progress and activities.
Last updated Tuesday, November 27, 2018